Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.51 |
| ▸ | MAOB | P27338 | 6/20 | 0.51 |
| ▸ | GRM6 | O15303 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745387 | 1.00 | MAOA (0.51) | MAOAMAOBGRM6AGTR2S1PR5 | |
| SCHEMBL23243788 | 1.00 | MAOA (0.51) | MAOAMAOBGRM6AGTR2S1PR5 | |
| SCHEMBL14555989 | 1.00 | MAOA (0.51) | MAOAMAOBGRM6AGTR2S1PR5 | |
| SCHEMBL16764924 | 1.00 | MAOA (0.51) | MAOAMAOBGRM6AGTR2S1PR5 | |
| SCHEMBL7067401 | 0.88 | MAOB (0.64) | MAOAMAOBGRM6 | |
| SCHEMBL28218104 | 0.88 | MAOB (0.64) | MAOAMAOBGRM6 | |
| Hydrochloric Acid SCHEMBL28218107 | 0.87 | MAOB (0.63) | MAOAMAOBGRM6 | |
| SCHEMBL16764868 | 0.85 | MAOA (0.47) | MAOAMAOBMAPT | |
| SCHEMBL4247443 | 0.85 | MAOA (0.47) | MAOAMAOBMAPT | |
| SCHEMBL28431385 | 0.85 | MAOA (0.47) | MAOAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | PFIZER INC. (US) | 2023-12-21 | — | — | US | disclosed |
| EP-4038060-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-11471458-B2 | Diacylglycerol acyl transferase 2 inhibitor | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11065249-B2 | Diacylglycerol acyl transferase 2 inhibitor | PFIZER INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210100798-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR | PFIZER INC. (US) | 2021-04-08 | — | — | US | disclosed |
| WO-2021064590-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR | PFIZER INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210100796-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR | PFIZER INC. (US) | 2021-04-08 | — | — | US | disclosed |
| CN-111372927-A | Tricyclic compounds as histone methyltransferase inhibitors | 全球血液疗法股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3668863-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065249-B2 | Diacylglycerol acyl transferase 2 inhibitor | DGAT2, DGAT1, ACAT2 | MAOA 2466/4885MAOB 1403/4885GRM6 3009/4885 |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | MAOA 3265/4885MAOB 3310/4885GRM6 2068/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | MAOA 3265/4885MAOB 3310/4885GRM6 2068/4885 |
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | ACAT2, ACACB, ACACA | MAOA 1212/4885MAOB 1645/4885GRM6 3927/4885 |
| US-20210100798-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR | DGAT2, DGAT1, ACAT2 | MAOA 2462/4885MAOB 1420/4885GRM6 3011/4885 |
| US-11471458-B2 | Diacylglycerol acyl transferase 2 inhibitor | DGAT2, DGAT1, ACAT2 | MAOA 2466/4885MAOB 1403/4885GRM6 3009/4885 |
| US-20210100796-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR | DGAT2, DGAT1, ACAT2 | MAOA 2466/4885MAOB 1403/4885GRM6 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.